Characteristics | Discovery cohort | Internal validation cohort | GSE31312 cohort | GSE10846 cohort | GSE4475 cohort |
---|---|---|---|---|---|
No. of patients | 213 | 213 | 426 | 350 | 129 |
Age, year | |||||
 >60 | 121 | 123 | 244 | 196 | 72 |
 ≤60 | 92 | 90 | 182 | 154 | 57 |
Gender | |||||
 Female | 101 | 82 | 183 | 152 | 54 |
 Male | 112 | 131 | 243 | 184 | 74 |
 Unknown | 14 | 1 | |||
Stage | |||||
 I/II | 97 | 106 | 203 | 160 | 36 |
 III/IV | 116 | 107 | 223 | 184 | 48 |
 Unknown | 6 | 45 | |||
No. of extranodal sites | |||||
 <2 | 167 | 170 | 337 | 299 |  |
 ≥2 | 46 | 43 | 89 | 26 | |
 Unknown | 25 | ||||
LDH | |||||
 0 | 72 | 61 | 133 | 140 | |
1 | 120 | 133 | 253 | 156 | |
Unknown | 21 | 19 | 40 | 54 | |
ECOG | |||||
 <2 | 168 | 171 | 339 | 256 |  |
 ≥2 | 45 | 42 | 87 | 74 | |
Unknown | 20 | ||||
Subtype | |||||
 GCB | 106 | 121 | 227 | 183 | 74 |
 ABC | 107 | 92 | 199 | 167 | 55 |
Unclassified | |||||
Survival status | |||||
Dead | 80 | 74 | 154 | 143 | 51 |
Alive | 133 | 139 | 272 | 207 | 42 |
Unknown | 36 |